Loading news...
Shares of Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) have earned an average rating of "Moderate Buy" from the sixteen research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating on the company. The average 12-month
The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the market, as growth in other sectors of the economy have led to valuations that now look more elevated than the biotech sector (in many cases).
Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI pre-treated advanced ALK-positive NSCLC population planned for the first half of 2026 Submission for potential indication expansion of zidesamtinib in TKI-naïve advanced ROS1-positive NSCLC population planned for the second half of 2026 Well capitalized with operating runway anticipated into 2029 Company to present at 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th at 9:00 a.m.
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) CFO Alexandra Balcom sold 4,236 shares of Nuvalent stock in a transaction on Monday, January 5th. The shares were sold at an average price of $97.32, for a total value of $412,247.52. Following the sale, the chief financial officer directly owned 84,914 shares of the company's stock, valued
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) insider Deborah Ann Miller sold 4,363 shares of Nuvalent stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $97.32, for a total value of $424,607.16. Following the completion of the transaction, the insider directly owned 44,723 shares of the company's
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) insider Christopher Durant Turner sold 4,236 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $97.32, for a total value of $412,247.52. Following the transaction, the insider owned 58,311 shares of the company's stock, valued
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) CEO James Richard Porter sold 17,890 shares of Nuvalent stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $97.32, for a total transaction of $1,741,054.80. Following the transaction, the chief executive officer directly owned 288,172 shares of the company's stock,
Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.
Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.
CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an undisclosed third party for up to $315 million.
CAMBRIDGE, Mass. , Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron Squarer to its Board of Directors.
Fisher Asset Management LLC decreased its holdings in Nuvalent, Inc. (NASDAQ: NUVL) by 5.4% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 114,761 shares of the company's stock after selling 6,577 shares during the quarter. Fisher Asset Management LLC owned 0.16% of
Creative Planning increased its stake in shares of Nuvalent, Inc. (NASDAQ: NUVL) by 110.6% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,288 shares of the company's stock after buying an additional 9,079 shares during the quarter. Creative Planning's
Stock News Campbell puts exec on leave: Campbell's Co. (CPB) sidelined a senior IT executive after a lawsuit and leaked audio alleged he disparaged customers an
CAMBRIDGE, Mass. , Nov. 26, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
Guru Stock PicksJefferies Group has made the following transactions:Reduce in CLDX by 12.28%Sold out in UNFIAdd in SMH by 25.28%New position in XNCRT Rowe Price
CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its previously announced underwritten public offering of 4,950,496 shares of Class A common stock at a price to the public of $101.00 per share.
NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass. , Nov. 19, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for zidesamtinib, an investigational ROS1-selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least 1 prior ROS1 tyrosine kinase inhibitor (TKI).